Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;26(2):373-9.
doi: 10.1002/jbmr.217.

Relation of age, gender, and bone mass to circulating sclerostin levels in women and men

Ulrike I Mödder  1 , Kelley A Hoey, Shreyasee Amin, Louise K McCready, Sara J Achenbach, B Lawrence Riggs, L Joseph Melton 3rd, Sundeep Khosla
Affiliations

Relation of age, gender, and bone mass to circulating sclerostin levels in women and men

Ulrike I Mödder et al. J Bone Miner Res. 2011 Feb.

Abstract

Sclerostin is a potent inhibitor of Wnt signaling and bone formation. However, there is currently no information on the relation of circulating sclerostin levels to age, gender, or bone mass in humans. Thus we measured serum sclerostin levels in a population-based sample of 362 women [123 premenopausal, 152 postmenopausal not on estrogen treatment (ET), and 87 postmenopausal on ET] and 318 men, aged 21 to 97 years. Sclerostin levels (mean ± SEM) were significantly higher in men than women (33.3 ± 1.0 pmol/L versus 23.7 ± 0.6 pmol/L, p < .001). In pre- and postmenopausal women not on ET combined (n = 275) as well as in men, sclerostin levels were positively associated with age (r = 0.52 and r = 0.64, respectively, p < .001 for both). Over life, serum sclerostin levels increased by 2.4- and 4.6-fold in the women and men, respectively. Moreover, for a given total-body bone mineral content, elderly subjects (age ≥ 60 years) had higher serum sclerostin levels than younger subjects (ages 20 to 39 years). Our data thus demonstrate that (1) men have higher serum sclerostin levels than women, (2) serum sclerostin levels increase markedly with age, and (3) compared with younger subjects, elderly individuals have higher serum sclerostin levels for a given amount of bone mass. Further studies are needed to define the cause of the age-related increase in serum sclerostin levels in humans as well as the potential role of this increase in mediating the known age-related impairment in bone formation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Serum sclerostin levels versus age in (A) women and (B) men. Correlation coefficients are as noted.
Fig. 2
Fig. 2
Serum sclerostin levels versus total-body bone mineral content (TBBMC) in young (ages 20 to 39 years), middle-aged (40 to 59 years), and elderly (60+ years) women. Unadjusted and age-adjusted correlation coefficients are as noted.
Fig. 3
Fig. 3
Serum sclerostin levels versus total-body bone mineral content (TBBMC) in young (ages 20 to 39 years), middle-aged (40 to 59 years), and elderly (60+ years) men. Unadjusted and age-adjusted correlation coefficients are as noted.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Barons R, Rawadi G. Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148:2635–2643. - PubMed
    1. Krishnan V, Bryant HU, MacDougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116:1202–1209. - PMC - PubMed
    1. van Bezooijen RL, Roelen BAJ, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004;199:805–814. - PMC - PubMed
    1. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005;280:26770–26775. - PubMed
    1. Poole KES, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19:1842–1844. - PubMed

Publication types